personalized medicine

Personalized medicine: Right drug, right patient, right time
Personalized medicine: Right drug, right patient, right timeThe premise is to use a patient’s own genetic information to guide decisions for prevention, diagnosis, and treatment of disease and other health conditions.
Genetic testing in oncology: 5 things payers should knowAs genomics continues to evolve, here are five things to know about genetic testing and counseling.
Three improvements data promises to deliverPersonalized, prescriptive medicine creates higher-value care for patients
Personalized medicine brings big wins to managed careA new report reveals how personalized medicine can make patients healthier while lowering costs.
Five healthcare policies to expect under President TrumpAs Donald Trump was sworn in as the 45th U.S. president, health policy experts share with Managed Healthcare Executive what’s next for healthcare.
Four things health execs should know about the oncology pipeline
Four things health execs should know about the oncology pipelineHere’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care.
Biomarkers: Top challenges and opportunities in managed careBiomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.
Five ways health plans can ‘personalize’ the member experienceHere are five ways to use big data and predictive analytics to get insights about members and create a personalized member experience.
ARVO 2016 meeting paves path for personalized medicineEmerging trends and hot topics in eye and vision research filled the sessions at this year’s meeting of the Association for Research in Vision and Ophthalmology.
How biomarkers can personalize cancer immunotherapyASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies